SecuraBio: Lymphoma trials
The registry lists 11 Lymphoma studies with SecuraBio as lead sponsor. 1 are open to participants now and 7 have results posted.
Phase 1 1Phase 2 6Phase 3 4No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) PhenotypeRecruitingNCT06522737Phase 3
- A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin LymphomaCompletedNCT04038359Phase 2Results posted
- A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)CompletedNCT03372057Phase 2Results posted
- A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)TerminatedNCT02391545Phase 1/2Results posted
- Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular LymphomaTerminatedNCT02204982Phase 3Results posted
- A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07CompletedNCT02049515Phase 3Results posted
- A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)CompletedNCT02004522Phase 3Results posted
- A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin LymphomaCompletedNCT01882803Phase 2Results posted
- Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FLTerminatedNCT04342117
- Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic LymphomaWithdrawnNCT03370185Phase 2
- Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)WithdrawnNCT02605694Phase 2